USRE39497E1 - Storage of materials - Google Patents

Storage of materials Download PDF

Info

Publication number
USRE39497E1
USRE39497E1 US09/939,689 US93968901A USRE39497E US RE39497 E1 USRE39497 E1 US RE39497E1 US 93968901 A US93968901 A US 93968901A US RE39497 E USRE39497 E US RE39497E
Authority
US
United States
Prior art keywords
water
carrier substance
composition
stored
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US09/939,689
Inventor
Felix Franks
Ross H. M. Hatley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma AG
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898903593A external-priority patent/GB8903593D0/en
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Priority to US09/939,689 priority Critical patent/USRE39497E1/en
Assigned to NEKTAR THERAPEUTICS reassignment NEKTAR THERAPEUTICS CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: INHALE THERAPEUTIC SYSTEMS, INC.
Application granted granted Critical
Publication of USRE39497E1 publication Critical patent/USRE39497E1/en
Assigned to NOVARTIS PHARMA AG reassignment NOVARTIS PHARMA AG ASSIGNMENT OF PATENT RIGHTS Assignors: NEKTAR THERAPEUTICS
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/082Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • C12N11/087Acrylic polymers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/10Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a carbohydrate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Definitions

  • This invention relates to the stabilisation and storage of materials.
  • the principal envisaged field of application is materials employed in the biochemical field and some pharmaceuticals.
  • a few biologically active materials e.g. some proteins are sufficiently stable that they can be isolated, purified and then stored in solution at room temperature. For most materials however this is not possible and some more elaborate form of stabilisation/storage procedure must be used.
  • cryoprotectant additive present in sufficient concentration (e.g. glycerol) to depress the freezing point to below the storage temperature and so avoid freezing.
  • a cryoprotectant additive present in sufficient concentration (e.g. glycerol) to depress the freezing point to below the storage temperature and so avoid freezing.
  • glycerol e.g. glycerol
  • the enzymes need to be protected against freezing by the addition of high concentrations of glycerol and maintained at ⁇ 20° C.
  • Use of an additive in high concentration may also reduce the specificity of restriction enzymes and give rise to so-called “star-activity”. (B. Polisky et al. PNAS USA, 72, 3310 (1975)).
  • this invention provides a storable composition
  • a storable composition comprising at least one material to be stored, preferably selected from the group consisting of proteins, peptides, nucleosides, nucleotides and enzyme cofactors, dissolved in a water-soluble or water-swellable substance which is in an amorphous, glassy or (much less preferably) rubbery state.
  • the composition displays a glass transition temperature of at least 20° C. preferably at least 30° C.
  • the composition has a water content of not more than 4% by weight.
  • the invention may be utilised for stable storage of a single material, or for a mixture of materials which have little or no effect on each other.
  • a single composition contains a plurality of materials which form part or all of a reacting system. These may be fairly simple chemicals.
  • this invention provides a method of rendering a material suitable for storage, comprising dissolving the material in a water-soluble or water-swellable substance or solution thereof and forming the resulting mixture into a glass.
  • This process is capable of being carried out without the use of any non-aqueous organic solvent, which is advantageous because such solvent could prove harmful to many substances. Also processing with and/or removal of organic solvents can be undesirable for environmental reasons.
  • a further feature is that the process is energy efficient, requiring much less energy than freeze drying. Most of the drying can be done at less than 40° C.
  • the material(s) stabilized for storage may potentially be any of a wide range of materials which are ordinarily liable to undergo a chemical reaction which is dependent on diffusion of reacting species.
  • proteins and peptides including derivatives thereof such as glycoproteins.
  • proteins and peptides may be any of enzymes, transport proteins, e.g. haemoglobin, immunoglobulins, hormones, blood clotting factors and pharmacologically active proteins or peptides.
  • nucleosides nucleotides, dinucleotides, oligonucleotides (say containing up to four nucleotides) and also enzyme cofactors, whether or not these are nucleotides.
  • Enzyme substrates in general are materials to which the invention may be applied.
  • the material for stabilisation and storage may be isolated from a natural source, animal, plant, fungal or bacterial, or may be produced by and isolated from cells grown by fermentation in artificial culture. Such cells may or may not be genetically transformed cells.
  • the material will need to be soluble in aqueous solution, at least to the extent of forming a dilute solution which can be used for incorporation into the glass forming substance.
  • a development of this invention is to store more than one component of a reacting system in a glass. This can be useful for materials which will be required to be used together in, for example, an assay or a diagnostic kit.
  • one or more of the materials may be a protein, peptide, nucleoside, nucleotide or enzyme cofactor. It is also possible that the materials may be simpler species. For instance a standard assay procedure may require pyruvate and NADH to be present together. Both can be stored alone with acceptable stability. However, when brought together in aqueous solution they begin to react. If put together in required proportions in the glassy state they do not react and the glass can be stored.
  • a glass is defined as an undercooled liquid with a very high viscosity, that is to say at least 10 13 Pa.s, probably 10 14 Pa.s or more.
  • a glass presents the appearance of a homogeneous, transparent, brittle solid which can be ground or milled to a powder.
  • diffusive processes take place at extremely low rates, such as microns per year. Chemical or biochemical changes including more than one reacting moiety are practically inhibited.
  • the glass forming substance employed in this invention must be hydrophilic—either water-soluble or water-swellable—so that water will act as a plasticiser.
  • Many hydrophilic materials both of a monomeric and a polymeric nature either exist as or can be converted into amorphous states which exhibit the glass/rubber transitions characteristic of amorphous macromolecules. They have well defined glass transition temperatures T g which depend on the molecular weight and a molecular complexity of the glass forming substance. T g is depressed by the addition of diluents. Water is the universal plasticiser for all such hydrophilic materials. Therefore, the glass/rubber transition temperature is adjustable by the addition of water or an aqueous solution.
  • the glass forming substance when anhydrous or nearly so, displays a glass transition temperature T g in a range from 20 to 150° C., preferably 25 to 70° C. If T g is towards the higher end of the range, a lower T g can be achieved by adding water which can be removed after the material which is to be stored has been incorporated into the glass. Mixtures of glass forming substances may be used if the components are miscible as a solid solution. If so, material(s) of lower T g serve as plasticiser(s) for material(s) of higher T g .
  • T g of the final composition is sufficiently high, storage can be at room temperature. However, if T g of the composition is close to or below room temperature it may be necessary or desirable to refrigerate the glassy composition if storage is for a prolonged period. This is less convenient but still is more economical than freeze-drying.
  • composition If the composition is heated above its T g during storage, it will change to its rubbery state. Even in this condition stored materials are stable for a considerable period of time. Consequently, it may well do no harm if the temperature of the stored material is allowed to go above T g for a limited time, such as during transportation.
  • T g of the composition is well above room temperature, the composition is better able to withstand storage at an elevated temperature, e.g. in a hot climate.
  • T g of the formulated composition is typically 5° below T g of the anhydrous glass forming substance.
  • the glass forming substance should be sufficiently chemically inert towards the material which is to be incorporated in it.
  • An absolute absence of chemical reactivity may not be essential, as long as it is possible to incorporate the material, store the glass, and recover the material without serious degradation through chemical reaction.
  • Carbohydrates are an important group of glass forming substances: thus candy is a glassy form of sugar (glucose or sucrose).
  • the T g for glucose, maltose and maltotriose are respectively 31, 43 and 76° C. (L. Slade and H. Levine, Non-equilibrium behaviour of small carbohydrate-water systems, Pure Appl. Chem. 60 1841 (1988)).
  • Water depresses T g and for these carbohydrates the depression of T g by small amounts of moisture is approximately 6° C. for each percent of moisture added.
  • polyhydroxy compounds can be used, such as carbohydrate derivates like sorbitol and chemically modified carbohydrates.
  • glass forming substances are water-soluble or water-swellable synthetic polymers, such as polyvinyl pyrrolidone, polyacrylamide or polyethyleneimine.
  • T g is a function of the molecular weight. Both of these classes of glass forming substances are suitable for the present invention.
  • a group of glass forming substances which may in particular be employed are sugar copolymers described in U.S. Pat. No. 3,300,474 and sold by Pharmacia under the Registered Trade Mark “Ficoll”.
  • This U.S. patent describes the materials as having molecular weight 5,000 to 1,000,000 and containing sucrose residues linked through ether bridges to bifunctional groups.
  • Such groups may be alkylene of 2, 3 or more carbon atoms but not normally more than 10 carbon atoms.
  • the bifunctional groups serve to connect sugar residues together.
  • These polymers may for example be made by reaction of the sugar with a halohydrin or a bis-epoxy compound.
  • One process of rendering a material storage stable in accordance with the present invention commences from an aqueous solution of the material (which will be referred to as the active material), and a supply of the substance into which it is to be incorporated, with this substance already in an amorphous state, either glassy or rubbery.
  • the materials are mixed to homogenise the glass forming substance with the active material.
  • the rubbery form has the consistency of a dough and can be rolled or milled into a thin sheet. This rubber is then subjected to reduced pressure, possibly accompanied by moderate heat, in order to remove most of the added moisture.
  • the final product is a glass with a glass temperature slightly, e.g. approximately 5°, below that of the pure glass forming substance. It can be kept in the form of a transparent film or ground into a fine powder or compressed into tablet form.
  • the glass forming substance and the amount of solution added to it are chosen so that the rubbery material
  • the starting substance also has its T g above ambient temperature, so that lowering of T g on addition of aqueous solution lowers this value from above ambient to below.
  • T g above ambient temperature
  • the amount of aqueous solution which can and should be added to form a rubbery dough may well be found by trial and error. It is likely to be not more than 5% by weight based on the glass forming substance.
  • the steps of adding solution to form a rubbery dough and drying this back to a glassy state can be repeated to build up the concentration of active material in the glass.
  • the T g value of a sample of a glass forming substance can be determined, and determined again after mixing in varying amounts of water, so as to be able to plot a graph of T g against moisture content.
  • T g values can be determined with a differential scanning calorimeter and can be detected as a point at which a plot of heat input against temperature passes through an inflection point—giving a maximum of the first temperature derivative.
  • Vacuum applied to assist the removal of water from the rubbery composition need not be particularly hard. Suitably it is less than 90% of normal atmospheric pressure. A pressure which is 80% of normal atmospheric pressure has been found adequate. A harder vacuum may be employed, however, if this is found convenient.
  • Heating of the doughy mixture to remove moisture may be at a temperature not above 80°, and for a protein is preferably not above 60° C. Heating may not be necessary: evaporation of moisture under reduced pressure may proceed to a sufficiently low moisture content even at room temperature of around 20° C., but of course heat accelerates the evaporation.
  • Another process for rendering material storage stable in accordance with the present invention can enable the material to be stored and recovered at a greater concentration of active material relative to the carrier substance.
  • a quantity of the carrier substance, or a solution thereof is added to a solution of the active material.
  • the solution may be divided into convenient portions, e.g. 0.1 to 1 ml.
  • the samples of solution are placed under reduced pressure so that water is evaporated from them until the carrier substance is in a glassy state. Typical conditions are to commence the evaporation at a temperature not exceeding 40° C., preferably in the range from 20 to 30° C. and continue it for some hours, for instance 24 to 36 hours. As evaporation continues the glass temperature of the residual material rises.
  • Evaporation for the period indicated can be sufficient to achieve a glass transition temperature exceeding 30° C.
  • the temperature may be raised while evaporation continues. For instance once the glass transition temperature has reached a level of 30° C. the temperature may be raised to within a range of 40 to 70° C., e.g. 60° C. for a shorter time such as two hours.
  • vacuum used to bring about evaporation of water does not need to be particularly hard. It may also be found that heating is unnecessary: evaporation without heating for an extended time may achieve a sufficiently low moisture content.
  • the carrier substance may be added in a dry state, e.g. a powder, or as a solution.
  • Recovery i.e. reactivation
  • stored material can be effected by simply adding water or aqueous solution to a quantity of the glass with the active material therein. If the carrier substance is water-soluble the result is a solution of the material and the earner substance.
  • the suitability of an intended glass forming substance and conditions for incorporation of material into it can both be checked by preparing a glass with the material incorporated, and then recovering the material without any substantial period of storage.
  • Storage stability can, if desired, be tested by storage at a higher temperature such as 35° C. or even 50° C. which gives an accelerated test.
  • Examples 1 to 4 illustrate the first process referred to above in which a solution containing the active material is incorporated into the glassy carrier substance, turning it temporarily into a rubbery state.
  • Examples 5 onwards illustrate the second process described above in which the carrier substance is added to a solution of the active material and the resulting solution is then evaporated to the glassy state.
  • material is stored at a temperature above ambient, to provide an accelerated test of storage life.
  • Examples 1 and 2 describe the storage of lactate dehydrogenase (LDH) which is assayed using a combination of NADH and pyruvate.
  • Example 4 shows the storage of the unstable mixture of NADH with pyruvate. This would provide a suitable material for use in carrying out LDH assays, but in Example 4 that assay procedure is used to confirm the activity of the NADH/pyruvate after storage.
  • LDH lactate dehydrogenase
  • Example 3 describes storage of restriction enzyme, and the activity of the stored enzyme is confirmed by showing that its effect on DNA remains unchanged.
  • the glass forming substance employed was Ficoll 400 DL (Pharmacia. Reg Trade Mark) which is a copolymer of sucrose and epichlorohydrin. It is water-soluble and has a T g of 97° C. 4 grams of the Ficoll was weighed (w s ) into a dry Universal tube. About 50% was placed into a dry mortar and 0.2 ml of a solution containing 1,000 units/ml lactate dehydrogenase LDH (ex rabbit muscle) in 0.01M phosphate buffer pH 7.0 was added and mixed well into the Ficoll. A further 0.2 ml of LDH solution was then incorporated into the mix. A small amount of Ficoll was added, until a dough was obtained which did not adhere to the pestle.
  • Ficoll 400 DL Pharmacia. Reg Trade Mark
  • the dough was rolled out on a tile to give a sheet of approx 1 mm thickness. It was separated from the tile with a knife and lightly replaced onto the tile which was then heated in an oven for 30 minutes at 45-50° C. The sheet was removed from the oven and ground to a fine free-flowing powder which was stored in a sealed tube. The unused Ficoll was weighed (w e ). The powder containing the LDH was stored in the laboratory where temperatures fluctuated between 20 and 35° C.
  • the actual LDH activity of the powder was assayed. On the assumption that the powder contained negligible moisture, the powder was dissolved in phosphate buffer (0.01M pH 7) to give a test solution calculated to be a 1 to 1,000 dilution of the original solution. This would contain 1 unit of LDH per ml if enzyme activity was entirely preserved. Its actual activity was determined by the following procedure (Hatley, Franks and Mathias, Process Biochemistry, December 1987 page 170).
  • ⁇ A the absorbance change per minute at 340 nm.
  • 6.25 a correction factor for the molar absorbance of NADH.
  • TCF a temperature correction factor which must be applied for assays performed at temperatures other than 25° C.
  • C the concentration of the protein (mg ml ⁇ 1 ). No loss of LDH activity could be detected after storage for 5 months.
  • the stability of the product was compared to that of a commercial LDH preparation in 2.1M ammonium sulphate (Type II, 10,000 units/ml ex Sigma) which was stored at 25° C. and assayed periodically by the above method.
  • the activity of this commercial preparation decreased on average by 1.2% per day over the first 45 days.
  • a quantity of crystalline sucrose was gently heated to melting on a hotplate under a dry, oxygen-free atmosphere. (Dry nitrogen was used). The sucrose was allowed to cool to give a transparent glass and was then ground into a line powder, still under a dry atmosphere, and stored in a stoppered tube, 0.4 ml of an LDH solution, containing 4,000 units/ml, in 0.01M phosphate buffer pH 7.0 was added to 4 g of the sucrose glass and mixed using a pestle and mortar. The resulting paste was rolled out on a tile into a thin sheet which was then freed from, and lightly replaced on the tile. It was next heated in an oven for 30 minutes at 40-50° C. after which it was allowed to cool.
  • the preparation was assayed periodically for LDH activity, as described in Example 1. No loss of activity could be detected after 1 month storage at 25° C.
  • the glass temperature of the preparation was determined by differential scanning calorimetry as 32° C.
  • An assay for enzyme activity was carried out by the following procedure (which is taken from LKB Laboratory Manual: LKB 2013 Miniphor Submarine Electrophoresis Unit 1985, Chapter 6). The solution was incubated with 1 ⁇ g lamda-DNA for 1 hour at 37° C. Electrophoresis of the incubation mixture was then carried out on Q.5% agarose gel in Tris/borate buffer in standard manner. The DNA breakdown bands observed on the gel corresponded exactly with those of a control run with a fresh enzyme solution.
  • a solution containing 100 mg/ml NADH and 33 mg/ml pyruvate was prepared. 0.4 ml of this solution were incorporated into 4 g of a sucrose glass and the mixture processed, as described in Example 2.
  • the mixed glass was stored in 20 mg quantities in spectrophotometer cuvettes which were closed with sealing film and kept in a laboratory where the temperature fluctuated between 20 and 35° C. The glass was stored for 14 days.
  • the contents of a cuvette were dissolved in 2.7ml of 0.01M phosphate buffer (pH 7.0) and 0.1 ml of a LDH solution containing 1 unit/ml was added.
  • the absorbance at 340 nm was recorded at 30 second intervals for a total period of 3 minutes and the temperature of the solution was measured.
  • the apparent LDH enzyme activity was determined from the period during which the absorbance change was linear with time. The activity was calculated as in Example 1.
  • a control assay was carried out with fresh solutions of NADH and pyruvate. The apparent activity obtained using the dissolved glass closely matched the control value.
  • the active material was glutamate dehydrogenase. 532 mg of Ficoll 400 DL as used to Example 1 was added to 20 ml of a glutamate dehydrogenase solution, containing 13.3 mg/ml protein. The protein:Ficoll ratio was therefore 1.2. The sample was then divided into eighty 0.25 ml portions and dried at 37° C. under reduced pressure (about 80% of atmospheric) for 24 hours. The sample was then divided into two batches of 40 vials. One batch was heated under reduced pressure for a further two hours at 60° C. The batches were then further subdivided and stored under a range of conditions (see below).
  • Vials were periodically rehydrated by adding 2.23 ml of 50 mM Tris/HCl buffer at pH 7.5, containing 0.3 mM EDTA to give a solution which, assuming no loss of activity, would have contained 100 units of enzyme per ml. This was serially diluted to 1 unit/ml in the same buffer. The actual activity of the recovered enzyme was determined.
  • the assay procedure for recovered enzyme made use of the following solutions:
  • Assay was carried out using a standard assay procedure published by Boeringer Mannheim. The assay monitors the decrease in absorbance at 245 nm as the enzyme catalyses the oxidation of a known solution of ascorbic acid. Enzyme which had been stored for 2 months at 35° C. was found, within the limits of experimental error, to have the same activity as enzyme which was stored for only a very short time.
  • Lactate dehydrogenase was incorporated into Ficoll 400 using the procedure of Example 5.
  • the Ficoll:enzyme ratio was 0.23:0.26.
  • Samples were stored for various periods and then recovered by adding 0.01M phosphate buffer in a quantity which would give a theoretical activity of 1 unit/ml, assuming full retention of activity.
  • the recovered solutions were assayed using the procedure set out in Example 1.
  • the measured activity of recovered material, as a percentage of the theoretical activity was:
  • Cytochrome C reductase was incorporated into Ficoll 400 by the procedure of Example 5. The ratio of enzyme:Ficoll was 1:1. Samples were subjected to an accelerated test, viz. stored for 14 days at 35° C., and then recovered by adding 4 ml of 0.2M KHCO 3 to give a solution with a theoretical activity of 0.87 unit/ml assuming full retention of activity. The recovered material was assayed using a procedure given in “Methods in Enzymology” by Mahler, Volume II 1955 p. 688. It was found that the recovered material had an activity of 88% of the theoretical value.
  • Glycerol-3-phosphate dehydrogenase was incorporated into Ficoll 400 by the procedure of Examples. The ratio of enzyme:Ficoll was 1:2. Samples were subjected to an accelerated storage test by storage at 35° C. After 7 days storage the material was recovered by adding 0.05M Tris/HCl buffer at pH 7.6. This also contained 2 mg/ml albumin and 0.74 mg/ml EDTA. The recovered material was assayed using a procedure published by Biozyme Laboratories in which the enzyme catalyses the reaction: and the oxidation of NADH is followed spectrophotometrically at 340 nm.
  • Alpha-glucosidase was incorporated into Ficoll 400 using the procedure of Example 5.
  • the Ficoll:enzyme ratio was 1:1.
  • samples were stored for various periods at 35° C. and then recovered by adding 4 mls of 0.067M phosphate buffer at pH 7.0 to give a solution whose theoretical activity, assuming full retention of activity, was 2 units/ml.
  • the recovered solutions were assayed by a procedure described by H. Halvorson, Methods in Enzymology 8 559 (1966). The actual activity of recovered material relative to the theoretical value was:
  • NADH 5 g of Ficoll 400 was added to 20 ml of a 2 mg/ml NADH solution. This was divided into 40 portions, each containing 0.25 ml, and processed as in Example 5 to give glasses.
  • NADH and pyruvate were processed as in Example 11. Portions of each resulting glass powder were mixed together. One such mixture was at once rehydrated and assayed by the procedure of Example 4.
  • the reaction mixture consisted of 2.8 mls 0.01M phosphate buffer, 0.1 ml of rehydrated NADH/pyruvate mixture, and 0.1 mls of 1 unit/ml enzyme solution. The change in absorbance at 340 nm over three minutes was defined as 100%.
  • a range of carrier materials were used in a standard procedure in which the stored active material is lactate dehydrogenase.
  • a solution consisting of 0.05 g of carrier dissolved in 100 ml 0.01M phosphate buffer was prepared. 1 ml of 10 mg/ml lactate dehydrogenase solution was then added to 20 ml of the prepared solution. The solution thus created was divided into 0.5 ml aliquots in glass vials. These were dried under reduced pressure of about 80% atmospheric in a vacuum oven at 36° C. for 24 hours. After drying the vials were sealed and stored at ambient temperature. The product had a carrier:protein ratio by weight of 1:0.22.

Abstract

A material or mixture of materials which is not itself storage stable is rendered storage stable by incorporation into a water-soluble or swellable glassy or rubbery composition which can then be stored at ambient temperature. Recovery is by adding aqueous solution to the composition.

Description

Notice: More than one Reissue Application has been filed for the reissue of U.S. Pat. No. 5,098,893. The Reissue Applications are application Ser. Nos. 09/270,791; 09/939,688; and 09/939,689. Application Ser. Nos. 09/939,688 and 09/939,689 are continuation reissue applications of application Ser. No. 09/270,791, filed Mar. 17, 1999. Application Ser. No. 09/270,791 issued as RE 37,872 on Oct. 8, 2002. Application Ser. No. 09/939,688 issued as RE38,385 on Jan. 13, 2004.
This invention relates to the stabilisation and storage of materials. The principal envisaged field of application is materials employed in the biochemical field and some pharmaceuticals.
A few biologically active materials (e.g. some proteins) are sufficiently stable that they can be isolated, purified and then stored in solution at room temperature. For most materials however this is not possible and some more elaborate form of stabilisation/storage procedure must be used.
A “repertoire” of techniques is known. Not all of them are useful for all materials that give rise to a storage problem. Known storage/stabilisation techniques which are applied to materials after isolation into an aqueous suspension or solution are:
(i) Addition of high concentration of chemical “stabilizer” to the aqueous solution or suspension. Typically 3M ammonium sulphate is used. However, such additives can alter the measured activity of enzymes and can give ambiguous or misleading results if the enzyme is used in a test procedure. (R. H. M. Hatley and F. Franks. Variation in apparent enzyme activity in two-enzyme assay systems: Phosphoenolpyruvate carboxylase and malate dehydrogenase. Biotechnol. Appl. Biochem. 11. 367-370 (1989)). In the manufacture of diagnostic kits based on multi-enzyme assays, such additives often need to be removed before the final formulation. Such removal, by dialysis, often reduces the activity of an enzyme.
(ii) Freeze/thaw methods in which the preparation, usually mixed with an additive (referred to as a cryoprotectant) is frozen and stored, usually below −50° C., sometimes in liquid nitrogen. Not all proteins will survive a freeze/thaw cycle.
(iii) Cold storage, with a cryoprotectant additive present in sufficient concentration (e.g. glycerol) to depress the freezing point to below the storage temperature and so avoid freezing. For example in the case of restriction endonucleases, the enzymes need to be protected against freezing by the addition of high concentrations of glycerol and maintained at −20° C. Use of an additive in high concentration may also reduce the specificity of restriction enzymes and give rise to so-called “star-activity”. (B. Polisky et al. PNAS USA, 72, 3310 (1975)).
(iv) The commonest method for the stabilisation of isolated protein preparations freeze-drying, but this process can only be applied to freeze-stable products. The aqueous isolate of the active material in a suitable pH buffer and in the presence of a cryoprotectant is first frozen, typically to −40° to −50° C.; the ice is then removed by sublimation under vacuum and at low sub-zero temperatures, following which the residual moisture which may amount up to 50% of the “dried” preparation is removed by desorption during which the temperature gradually rises. The complete freeze-drying cycle may take several days and is costly in capital and energy. Freeze-drying also suffers from technical disadvantages because of its irreproducibility. Suppliers of freeze-dried protein products generally specify storage at −20° C. rather than ambient temperature. Exposure to ambient temperatures for periods of days to weeks can result in significant activity losses.
(v) Undercooling, as described in European Patent 0 136 030 and by Hatley et al. (Process Biochem. 22 169 (1987)) allows for the long-term (years) stabilisation of proteins without the need for additives. However, while this process extended the previous repertoire of possibilities, the undercooled preparations need to be shipped at temperatures not exceeding +5° C. and must be stored, preferably at −20° C. They also have to be recovered from a water-in-oil dispersion prior to their final use.
It will thus be apparent that a stabilisation/storage process which enabled storage at ambient temperature would be very desirable, since it would avoid the need for low temperature storage entailed by existing processes. Hitherto, however, storage at ambient temperature has been impossible for many materials.
There would also be advantage in adding to the existing “repertoire” of processes for stabilisation and storage, because some of the existing processes are limited in their applications or entail accepting disadvantages such as a need to mix with a stabilising agent which is difficult to remove later.
There would furthermore be advantage in providing a more cost effective process than the current freeze-drying process.
We have found, surprisingly, that materials which are not stable when isolated and held in solution at room temperature can nevertheless be successfully incorporated into a glass formed from a water-soluble or water-swellable substance, and can later be recovered. While in the glass the material is immobilised and stable.
In a first aspect this invention provides a storable composition comprising at least one material to be stored, preferably selected from the group consisting of proteins, peptides, nucleosides, nucleotides and enzyme cofactors, dissolved in a water-soluble or water-swellable substance which is in an amorphous, glassy or (much less preferably) rubbery state.
As will be explained in more detail below, it is preferred that the composition displays a glass transition temperature of at least 20° C. preferably at least 30° C.
It may be desirable that the composition has a water content of not more than 4% by weight.
The invention may be utilised for stable storage of a single material, or for a mixture of materials which have little or no effect on each other.
However, in a development of this invention, a single composition contains a plurality of materials which form part or all of a reacting system. These may be fairly simple chemicals.
In a further aspect, this invention provides a method of rendering a material suitable for storage, comprising dissolving the material in a water-soluble or water-swellable substance or solution thereof and forming the resulting mixture into a glass.
This process is capable of being carried out without the use of any non-aqueous organic solvent, which is advantageous because such solvent could prove harmful to many substances. Also processing with and/or removal of organic solvents can be undesirable for environmental reasons.
A further feature is that the process is energy efficient, requiring much less energy than freeze drying. Most of the drying can be done at less than 40° C.
MATERIAL STORED
The material(s) stabilized for storage may potentially be any of a wide range of materials which are ordinarily liable to undergo a chemical reaction which is dependent on diffusion of reacting species.
One category of materials to which the invention is applicable is proteins and peptides, including derivatives thereof such as glycoproteins. Such proteins and peptides may be any of enzymes, transport proteins, e.g. haemoglobin, immunoglobulins, hormones, blood clotting factors and pharmacologically active proteins or peptides.
Another category of materials to which the invention is applicable comprises nucleosides, nucleotides, dinucleotides, oligonucleotides (say containing up to four nucleotides) and also enzyme cofactors, whether or not these are nucleotides. Enzyme substrates in general are materials to which the invention may be applied.
The material for stabilisation and storage may be isolated from a natural source, animal, plant, fungal or bacterial, or may be produced by and isolated from cells grown by fermentation in artificial culture. Such cells may or may not be genetically transformed cells.
The material will need to be soluble in aqueous solution, at least to the extent of forming a dilute solution which can be used for incorporation into the glass forming substance.
As mentioned above, a development of this invention is to store more than one component of a reacting system in a glass. This can be useful for materials which will be required to be used together in, for example, an assay or a diagnostic kit.
Storing the materials as a single glassy preparation provides them in a convenient form for eventual use. For instance, if an assay requires a combination of a substrate, or cofactor and an enzyme, two or all three could be stored in a glass in the required concentration ratio and be ready for use in the assay.
If multiple materials are stored, they may be mixed together in an aqueous solution and then incorporated together into a glass. Alternatively they may be incorporated individually into separate glasses which are then mixed together.
When multiple materials are stored as a single composition (which may be two glasses mixed together) one or more of the materials may be a protein, peptide, nucleoside, nucleotide or enzyme cofactor. It is also possible that the materials may be simpler species. For instance a standard assay procedure may require pyruvate and NADH to be present together. Both can be stored alone with acceptable stability. However, when brought together in aqueous solution they begin to react. If put together in required proportions in the glassy state they do not react and the glass can be stored.
THE GLASS-FORMING SUBSTANCE
A glass is defined as an undercooled liquid with a very high viscosity, that is to say at least 1013 Pa.s, probably 1014 Pa.s or more.
Normally a glass presents the appearance of a homogeneous, transparent, brittle solid which can be ground or milled to a powder. In a glass, diffusive processes take place at extremely low rates, such as microns per year. Chemical or biochemical changes including more than one reacting moiety are practically inhibited.
Above a temperature known a the glass transition temperature Tg, the viscosity drops rapidly and the glass turns into a rubber, then into a deformable plastic which at even higher temperatures turns into a fluid.
The glass forming substance employed in this invention must be hydrophilic—either water-soluble or water-swellable—so that water will act as a plasticiser. Many hydrophilic materials, both of a monomeric and a polymeric nature either exist as or can be converted into amorphous states which exhibit the glass/rubber transitions characteristic of amorphous macromolecules. They have well defined glass transition temperatures Tg which depend on the molecular weight and a molecular complexity of the glass forming substance. Tg is depressed by the addition of diluents. Water is the universal plasticiser for all such hydrophilic materials. Therefore, the glass/rubber transition temperature is adjustable by the addition of water or an aqueous solution.
For this invention it will generally be necessary that the glass forming substance, when anhydrous or nearly so, displays a glass transition temperature Tg in a range from 20 to 150° C., preferably 25 to 70° C. If Tg is towards the higher end of the range, a lower Tg can be achieved by adding water which can be removed after the material which is to be stored has been incorporated into the glass. Mixtures of glass forming substances may be used if the components are miscible as a solid solution. If so, material(s) of lower Tg serve as plasticiser(s) for material(s) of higher Tg.
If Tg of the final composition is sufficiently high, storage can be at room temperature. However, if Tg of the composition is close to or below room temperature it may be necessary or desirable to refrigerate the glassy composition if storage is for a prolonged period. This is less convenient but still is more economical than freeze-drying.
If the composition is heated above its Tg during storage, it will change to its rubbery state. Even in this condition stored materials are stable for a considerable period of time. Consequently, it may well do no harm if the temperature of the stored material is allowed to go above Tg for a limited time, such as during transportation.
If a composition is maintained above its Tg (and therefore in a rubbery condition) the storage life will be limited but still considerable and the benefit of the invention will be obtained to a reduced extent.
Conversely, if Tg of the composition is well above room temperature, the composition is better able to withstand storage at an elevated temperature, e.g. in a hot climate.
As mentioned above, Tg of the formulated composition is typically 5° below Tg of the anhydrous glass forming substance.
The glass forming substance should be sufficiently chemically inert towards the material which is to be incorporated in it. An absolute absence of chemical reactivity may not be essential, as long as it is possible to incorporate the material, store the glass, and recover the material without serious degradation through chemical reaction.
Many organic substances and mixtures of substances will form a glassy state on cooling from a melt.
Carbohydrates are an important group of glass forming substances: thus candy is a glassy form of sugar (glucose or sucrose). The Tg for glucose, maltose and maltotriose are respectively 31, 43 and 76° C. (L. Slade and H. Levine, Non-equilibrium behaviour of small carbohydrate-water systems, Pure Appl. Chem. 60 1841 (1988)). Water depresses Tg and for these carbohydrates the depression of Tg by small amounts of moisture is approximately 6° C. for each percent of moisture added. We have determined the Tg value for sucrose as 55° C.
In addition to straightforward carbohydrates, other polyhydroxy compounds can be used, such as carbohydrate derivates like sorbitol and chemically modified carbohydrates.
Another important class of glass forming substances are water-soluble or water-swellable synthetic polymers, such as polyvinyl pyrrolidone, polyacrylamide or polyethyleneimine. Here Tg is a function of the molecular weight. Both of these classes of glass forming substances are suitable for the present invention.
A group of glass forming substances which may in particular be employed are sugar copolymers described in U.S. Pat. No. 3,300,474 and sold by Pharmacia under the Registered Trade Mark “Ficoll”. This U.S. patent describes the materials as having molecular weight 5,000 to 1,000,000 and containing sucrose residues linked through ether bridges to bifunctional groups. Such groups may be alkylene of 2, 3 or more carbon atoms but not normally more than 10 carbon atoms. The bifunctional groups serve to connect sugar residues together. These polymers may for example be made by reaction of the sugar with a halohydrin or a bis-epoxy compound.
One process of rendering a material storage stable in accordance with the present invention commences from an aqueous solution of the material (which will be referred to as the active material), and a supply of the substance into which it is to be incorporated, with this substance already in an amorphous state, either glassy or rubbery.
Then a controlled amount of an aqueous solution containing the active material is incorporated into the glassy substance, thus turning it into a rubber: the materials are mixed to homogenise the glass forming substance with the active material. The rubbery form has the consistency of a dough and can be rolled or milled into a thin sheet. This rubber is then subjected to reduced pressure, possibly accompanied by moderate heat, in order to remove most of the added moisture. The final product is a glass with a glass temperature slightly, e.g. approximately 5°, below that of the pure glass forming substance. It can be kept in the form of a transparent film or ground into a fine powder or compressed into tablet form. In the glassy state (below Tg) the deterioration of the active material, by whatever mechanism, is retarded to the extent that, on practical time-scales, even substances which in their free states are extremely labile are found to possess long shelf-lives.
Full biochemical activity is maintained, but locked in, throughout this period at temperatures below Tg and can be rapidly released by resolubilization of the glass in an aqueous medium.
The glass forming substance and the amount of solution added to it are chosen so that the rubbery material
obtained from the addition is at a temperature above its Tg (or to put it another way, its Tg is below the ambient temperature) but as moisture is removed the value of Tg increases to above the ambient temperature.
Preferably the starting substance also has its Tg above ambient temperature, so that lowering of Tg on addition of aqueous solution lowers this value from above ambient to below. However, it would be conceivable to begin with a moisture-containing substance whose Tg already lies below ambient, lower it further through addition of aqueous solution of the material to be incorporated, and finally raise Tg to above ambient temperature on drying.
The amount of aqueous solution which can and should be added to form a rubbery dough may well be found by trial and error. It is likely to be not more than 5% by weight based on the glass forming substance. The steps of adding solution to form a rubbery dough and drying this back to a glassy state can be repeated to build up the concentration of active material in the glass.
If desired, the Tg value of a sample of a glass forming substance can be determined, and determined again after mixing in varying amounts of water, so as to be able to plot a graph of Tg against moisture content.
Tg values can be determined with a differential scanning calorimeter and can be detected as a point at which a plot of heat input against temperature passes through an inflection point—giving a maximum of the first temperature derivative.
Vacuum applied to assist the removal of water from the rubbery composition need not be particularly hard. Suitably it is less than 90% of normal atmospheric pressure. A pressure which is 80% of normal atmospheric pressure has been found adequate. A harder vacuum may be employed, however, if this is found convenient.
Heating of the doughy mixture to remove moisture may be at a temperature not above 80°, and for a protein is preferably not above 60° C. Heating may not be necessary: evaporation of moisture under reduced pressure may proceed to a sufficiently low moisture content even at room temperature of around 20° C., but of course heat accelerates the evaporation.
Another process for rendering material storage stable in accordance with the present invention can enable the material to be stored and recovered at a greater concentration of active material relative to the carrier substance. In this process a quantity of the carrier substance, or a solution thereof, is added to a solution of the active material. When the added carrier substance has dissolved fully, the solution may be divided into convenient portions, e.g. 0.1 to 1 ml. The samples of solution are placed under reduced pressure so that water is evaporated from them until the carrier substance is in a glassy state. Typical conditions are to commence the evaporation at a temperature not exceeding 40° C., preferably in the range from 20 to 30° C. and continue it for some hours, for instance 24 to 36 hours. As evaporation continues the glass temperature of the residual material rises. Evaporation for the period indicated can be sufficient to achieve a glass transition temperature exceeding 30° C. Once such a sufficiently high glass transition temperature has been achieved the temperature may be raised while evaporation continues. For instance once the glass transition temperature has reached a level of 30° C. the temperature may be raised to within a range of 40 to 70° C., e.g. 60° C. for a shorter time such as two hours. For this procedure also, vacuum used to bring about evaporation of water does not need to be particularly hard. It may also be found that heating is unnecessary: evaporation without heating for an extended time may achieve a sufficiently low moisture content.
In the above, the carrier substance may be added in a dry state, e.g. a powder, or as a solution.
Recovery (i.e. reactivation) of stored material can be effected by simply adding water or aqueous solution to a quantity of the glass with the active material therein. If the carrier substance is water-soluble the result is a solution of the material and the earner substance.
Separation by chromatography to isolate the stored, active material from the glass forming substance is possible. However, in general it will be neither desirable nor necessary. Instead the glass forming substance is chosen so that it will not interfere with the use (e.g. assay) of the stored, active material.
In the case of a water-swellable glass forming substance, it will remain out of solution, perhaps as a gel, and the solution of the material can be separated by centrifugation if required.
The suitability of an intended glass forming substance and conditions for incorporation of material into it can both be checked by preparing a glass with the material incorporated, and then recovering the material without any substantial period of storage.
Storage stability can, if desired, be tested by storage at a higher temperature such as 35° C. or even 50° C. which gives an accelerated test.
EXAMPLES
In the examples which follow, Examples 1 to 4 illustrate the first process referred to above in which a solution containing the active material is incorporated into the glassy carrier substance, turning it temporarily into a rubbery state. Examples 5 onwards illustrate the second process described above in which the carrier substance is added to a solution of the active material and the resulting solution is then evaporated to the glassy state.
In some of the Examples, material is stored at a temperature above ambient, to provide an accelerated test of storage life.
Examples 1 and 2 describe the storage of lactate dehydrogenase (LDH) which is assayed using a combination of NADH and pyruvate. Example 4 shows the storage of the unstable mixture of NADH with pyruvate. This would provide a suitable material for use in carrying out LDH assays, but in Example 4 that assay procedure is used to confirm the activity of the NADH/pyruvate after storage.
Example 3 describes storage of restriction enzyme, and the activity of the stored enzyme is confirmed by showing that its effect on DNA remains unchanged.
EXAMPLE 1
The glass forming substance employed was Ficoll 400 DL (Pharmacia. Reg Trade Mark) which is a copolymer of sucrose and epichlorohydrin. It is water-soluble and has a Tg of 97° C. 4 grams of the Ficoll was weighed (ws) into a dry Universal tube. About 50% was placed into a dry mortar and 0.2 ml of a solution containing 1,000 units/ml lactate dehydrogenase LDH (ex rabbit muscle) in 0.01M phosphate buffer pH 7.0 was added and mixed well into the Ficoll. A further 0.2 ml of LDH solution was then incorporated into the mix. A small amount of Ficoll was added, until a dough was obtained which did not adhere to the pestle. The dough was rolled out on a tile to give a sheet of approx 1 mm thickness. It was separated from the tile with a knife and lightly replaced onto the tile which was then heated in an oven for 30 minutes at 45-50° C. The sheet was removed from the oven and ground to a fine free-flowing powder which was stored in a sealed tube. The unused Ficoll was weighed (we). The powder containing the LDH was stored in the laboratory where temperatures fluctuated between 20 and 35° C.
The LDH activity of the powder, assuming no loss of LDH activity, should be given by the relationship: LDH activity ( units / grams ) = approx 0.4 I ( w s - w r )
where I is the initial concentration of LD in the solution in units/ml.
The actual LDH activity of the powder was assayed. On the assumption that the powder contained negligible moisture, the powder was dissolved in phosphate buffer (0.01M pH 7) to give a test solution calculated to be a 1 to 1,000 dilution of the original solution. This would contain 1 unit of LDH per ml if enzyme activity was entirely preserved. Its actual activity was determined by the following procedure (Hatley, Franks and Mathias, Process Biochemistry, December 1987 page 170).
2.7ml of 0.01M phosphate buffer pH 7, 0.1 ml of 2 mg ml−1 NADH, and 0.1 ml of 10 mM pyruvate were placed into a cuvette of path length 10 mm. The cuvette was capped and shaken. 0.1 ml of the test solution was added and the cuvette again capped and shaken. The absorbance at 340 nm was recorded at 30 second intervals for a total period of three minutes. The temperature of the solution was also noted. A period during which the absorbance change was linear with time was selected and the absorbance change per minute, ΔA, calculated. The enzyme activity was calculated as follows: LDH  activity  (units  per  milligram) = Δ A × TCF 6.25 × C
where:
ΔA=the absorbance change per minute at 340 nm.
6.25=a correction factor for the molar absorbance of NADH.
TCF=a temperature correction factor which must be applied for assays performed at temperatures other than 25° C.
C=the concentration of the protein (mg ml−1). No loss of LDH activity could be detected after storage for 5 months.
The stability of the product was compared to that of a commercial LDH preparation in 2.1M ammonium sulphate (Type II, 10,000 units/ml ex Sigma) which was stored at 25° C. and assayed periodically by the above method. The activity of this commercial preparation decreased on average by 1.2% per day over the first 45 days.
EXAMPLE 2
A quantity of crystalline sucrose was gently heated to melting on a hotplate under a dry, oxygen-free atmosphere. (Dry nitrogen was used). The sucrose was allowed to cool to give a transparent glass and was then ground into a line powder, still under a dry atmosphere, and stored in a stoppered tube, 0.4 ml of an LDH solution, containing 4,000 units/ml, in 0.01M phosphate buffer pH 7.0 was added to 4 g of the sucrose glass and mixed using a pestle and mortar. The resulting paste was rolled out on a tile into a thin sheet which was then freed from, and lightly replaced on the tile. It was next heated in an oven for 30 minutes at 40-50° C. after which it was allowed to cool. It was then ground into a fine, free-flowing powder, all operations being performed under the exclusion of moisture. The powder was stored in an air-tight stoppered tube at 25° C. The LDH activity of the powder, assuming no loss of activity, should be given by:
LDH activity (units/g solid product)=approx. 0.1 I
where I is the initial LDH activity (units/ml) in the solution used to prepare the glass.
The preparation was assayed periodically for LDH activity, as described in Example 1. No loss of activity could be detected after 1 month storage at 25° C.
The glass temperature of the preparation was determined by differential scanning calorimetry as 32° C.
EXAMPLE 3
To 1 g Ficoll 400 were added 100 μl of a solution of EcoR I restriction endonuclease in 50% aqueous glycerol and a glass was prepared as described in Example 1. The final preparation was stored for 10 days in the laboratory with temperatures fluctuating between 20 and 30° C.
A quantity of the preparation equivalent to 2 units of enzyme, based on the assumption that the enzyme was still fully active, was dissolved in the following buffer: 100 mM Tris-HCl pH 7.5. 10 mM MgCl2. 50 mM NaCl. 0.1 mg/ml bovine serum albumin. An assay for enzyme activity was carried out by the following procedure (which is taken from LKB Laboratory Manual: LKB 2013 Miniphor Submarine Electrophoresis Unit 1985, Chapter 6). The solution was incubated with 1 μg lamda-DNA for 1 hour at 37° C. Electrophoresis of the incubation mixture was then carried out on Q.5% agarose gel in Tris/borate buffer in standard manner. The DNA breakdown bands observed on the gel corresponded exactly with those of a control run with a fresh enzyme solution.
EXAMPLE 4
A solution containing 100 mg/ml NADH and 33 mg/ml pyruvate was prepared. 0.4 ml of this solution were incorporated into 4 g of a sucrose glass and the mixture processed, as described in Example 2. The mixed glass was stored in 20 mg quantities in spectrophotometer cuvettes which were closed with sealing film and kept in a laboratory where the temperature fluctuated between 20 and 35° C. The glass was stored for 14 days.
For purposes of assay, the contents of a cuvette were dissolved in 2.7ml of 0.01M phosphate buffer (pH 7.0) and 0.1 ml of a LDH solution containing 1 unit/ml was added. The absorbance at 340 nm was recorded at 30 second intervals for a total period of 3 minutes and the temperature of the solution was measured. The apparent LDH enzyme activity was determined from the period during which the absorbance change was linear with time. The activity was calculated as in Example 1. A control assay was carried out with fresh solutions of NADH and pyruvate. The apparent activity obtained using the dissolved glass closely matched the control value.
EXAMPLE 5
The active material was glutamate dehydrogenase. 532 mg of Ficoll 400 DL as used to Example 1 was added to 20 ml of a glutamate dehydrogenase solution, containing 13.3 mg/ml protein. The protein:Ficoll ratio was therefore 1.2. The sample was then divided into eighty 0.25 ml portions and dried at 37° C. under reduced pressure (about 80% of atmospheric) for 24 hours. The sample was then divided into two batches of 40 vials. One batch was heated under reduced pressure for a further two hours at 60° C. The batches were then further subdivided and stored under a range of conditions (see below). Vials were periodically rehydrated by adding 2.23 ml of 50 mM Tris/HCl buffer at pH 7.5, containing 0.3 mM EDTA to give a solution which, assuming no loss of activity, would have contained 100 units of enzyme per ml. This was serially diluted to 1 unit/ml in the same buffer. The actual activity of the recovered enzyme was determined. The assay procedure for recovered enzyme made use of the following solutions:
Solutions
    • 1. 50 mM Tris/HCL pH 7.5+0.3 mM EDTA
    • 2. 4.5 mg/ml NADH in solution 1
    • 3. 4.0125 g NH4Cl in 25 ml H2O
    • 4. 97 mg α-ketoglutarate (disodium salt) in 50 ml solution 1.
To carry out the assay 2.6 ml of solution 4.0.2 ml of solution 3 and 0.1 ml of solution 2 were mixed in a 3 ml cuvette. 0.1 ml of the recovered enzymes solution was added. The absorbance at 340 nm was observed over 5 minutes and the activity of the enzyme calculated from the change (ΔA) in absorbance during the 5 minute period. Activity was calculated using the following formula: Activity  (units/ml) = Δ A × 3 5 × 0.622
The results obtained are set out in the following Table in which “initial activity” denotes the activity of enzyme which was recovered after only a minimal period of storage. The activities are quoted as percentages of the theoretical value of activity assuming this had been retained fully. A quantity of a commercially freeze-dried glutamate dehydrogenase (whose activity before freeze drying was stated by the supplier) was divided into several portions and stored at 25° C. for varying periods and assayed in the same way. Its activity is also quoted as percentages of the theoretical activity. The results for this material ar included in the Table.
Process Storage
Temp- Temp- Initial Duration of Storage (weeks)
erature erature Activity 1 2 3 4 6 12
37° C. ambient 97% 95% 99% 98% 86%
37° C. 35° C. 97% 78% 82% 87% 84%
37° C. 25° C. 130% 122% 121% 83% 69% 74%
60° C. ambient 103% 109% 96% 85% 98% 97%
60° C. 35° C. 103% 102% 105% 96% 116%
60° C. 25° C. 121% 114% 125% 84% 81% 89%
Freeze- 25° C. 56% 40% 35% 33% 36%
dried
As can be seen from these results, experimental error gives rise to some variation in FIGURES, but these do nevertheless show very substantial retention of activity over prolonged storage and much better retention of activity than with freeze-dried material.
EXAMPLE 6
2.50 ml of ascorbate oxidase (21.25 mg protein) solution was prepared. To this was added 2.50 ml of Tris buffer pH 7.6 containing 21.25 mg Ficoll 400, giving a protein:Ficoll weight ratio of 1:1. This was then divided into ten 0.5 ml portions and dried at 37° C. under reduced pressure of about 80% of atmospheric for 24 hours. The samples were next heated, still under reduced pressure, for a further two hours at 60° C. Storage was on a laboratory shelf (temperature fluctuations between 17 and 28° C.). After varying periods of storage, samples were rehydrated by addition of 2.5 ml of 0.4 mM Na2HPO4 containing 0.5% Bovine serum albumin. It was then serially diluted to more of the same solution so that its activity would be 0.2 units/ml, if activity had been fully retained, and assayed. The activity relative to the starting value was determined.
Assay was carried out using a standard assay procedure published by Boeringer Mannheim. The assay monitors the decrease in absorbance at 245 nm as the enzyme catalyses the oxidation of a known solution of ascorbic acid. Enzyme which had been stored for 2 months at 35° C. was found, within the limits of experimental error, to have the same activity as enzyme which was stored for only a very short time.
EXAMPLE 7
Lactate dehydrogenase was incorporated into Ficoll 400 using the procedure of Example 5. The Ficoll:enzyme ratio was 0.23:0.26. Samples were stored for various periods and then recovered by adding 0.01M phosphate buffer in a quantity which would give a theoretical activity of 1 unit/ml, assuming full retention of activity. The recovered solutions were assayed using the procedure set out in Example 1. The measured activity of recovered material, as a percentage of the theoretical activity was:
Before Storage period (days)
Drying 1 14 21 28 35 180
100% 91% 81% 91% 112% 97% 98%
EXAMPLE 8
Cytochrome C reductase was incorporated into Ficoll 400 by the procedure of Example 5. The ratio of enzyme:Ficoll was 1:1. Samples were subjected to an accelerated test, viz. stored for 14 days at 35° C., and then recovered by adding 4 ml of 0.2M KHCO3 to give a solution with a theoretical activity of 0.87 unit/ml assuming full retention of activity. The recovered material was assayed using a procedure given in “Methods in Enzymology” by Mahler, Volume II 1955 p. 688. It was found that the recovered material had an activity of 88% of the theoretical value.
EXAMPLE 9
Glycerol-3-phosphate dehydrogenase was incorporated into Ficoll 400 by the procedure of Examples. The ratio of enzyme:Ficoll was 1:2. Samples were subjected to an accelerated storage test by storage at 35° C. After 7 days storage the material was recovered by adding 0.05M Tris/HCl buffer at pH 7.6. This also contained 2 mg/ml albumin and 0.74 mg/ml EDTA. The recovered material was assayed using a procedure published by Biozyme Laboratories in which the enzyme catalyses the reaction:
Figure USRE039497-20070227-C00001

and the oxidation of NADH is followed spectrophotometrically at 340 nm.
It was found that after 7 days storage at 35° C. the activity was 96% of the activity of a control sample which was rehydrated immediately after being incorporated into Ficoll.
EXAMPLE 10
Alpha-glucosidase was incorporated into Ficoll 400 using the procedure of Example 5. The Ficoll:enzyme ratio was 1:1. As an accelerated test, samples were stored for various periods at 35° C. and then recovered by adding 4 mls of 0.067M phosphate buffer at pH 7.0 to give a solution whose theoretical activity, assuming full retention of activity, was 2 units/ml. The recovered solutions were assayed by a procedure described by H. Halvorson, Methods in Enzymology 8 559 (1966). The actual activity of recovered material relative to the theoretical value was:
Before Storage period (days at 35° C.)
Drying 1 4 11 90
100% 100% 103% 95% 70%
EXAMPLE 11
Pyruvate: 5 g of Ficoll 400 was added to 20 ml of 10 mM sodium pyruvate solution. The solution was then divided into 40 portions, each containing 0.25 ml portions and processed in the manner described for Example 5 to give glasses.
NADH: 5 g of Ficoll 400 was added to 20 ml of a 2 mg/ml NADH solution. This was divided into 40 portions, each containing 0.25 ml, and processed as in Example 5 to give glasses.
At intervals following storage one sample of each reagent was rehydrated and the solutions mixed. They were assayed by the standard method described in Example 4. After 3 months storage at ambient temperature their ability to react in the LDH assay was 100% of the control value obtained at the initiation of storage.
EXAMPLE 12
NADH and pyruvate were processed as in Example 11. Portions of each resulting glass powder were mixed together. One such mixture was at once rehydrated and assayed by the procedure of Example 4. The reaction mixture consisted of 2.8 mls 0.01M phosphate buffer, 0.1 ml of rehydrated NADH/pyruvate mixture, and 0.1 mls of 1 unit/ml enzyme solution. The change in absorbance at 340 nm over three minutes was defined as 100%.
A further mixture was stored for one week and then rehydrated and assayed in the same way. Within the limits of experimental error, its activity was the same. Thus there had been no reaction of the NADH and pyruvate during storage.
EXAMPLE 13
A range of carrier materials were used in a standard procedure in which the stored active material is lactate dehydrogenase. In each case, a solution consisting of 0.05 g of carrier dissolved in 100 ml 0.01M phosphate buffer was prepared. 1 ml of 10 mg/ml lactate dehydrogenase solution was then added to 20 ml of the prepared solution. The solution thus created was divided into 0.5 ml aliquots in glass vials. These were dried under reduced pressure of about 80% atmospheric in a vacuum oven at 36° C. for 24 hours. After drying the vials were sealed and stored at ambient temperature. The product had a carrier:protein ratio by weight of 1:0.22.
Some samples were rehydrated immediately by addition of phosphate buffer. Others were stored for various lengths of time and then rehydrated. The activity of enzyme was determined as in Example 1. Activity of enzyme is expressed, in each case, as activity relative to that of enzyme rehydrated in the first week after drying. Results are set out in the following Table, in which “PVP” denotes polyvinylpyrollidone, “GPS” denotes 6-O-α-D-glucopyranosyl-D-sorbitol. “Palatinit” is a product of Südzucker Aktiengesellschaft, Mannheim-Ochsenfurt. Germany, and consisting of an equimolecular mixture of α-D-glucopyranosyl-1,6-mannitol and α-D-glucopyranosyl-1,6-sorbitol.
Storage period at 25° C. (weeks)
Carrier 1 2 3 4 5 6 8 10 12 16
Malto- 100 114 91 96 68 71 101 94
trose
Poly- 100 132 123 103 116 146 103
dextrose
Inulin 100 99 91 95 114 98 91
Stachy- 100 122 137 140 109 106 127
ose
Dextran 100 81 71 89 102 91 95 84
Sorbose 100 93 75 76 55 66 65 58 62
Poly- 100 100 80 71 53 62 55 63
acryl-
amide
PVP 100 75 76 70 62
GPS 100 124
Pala- 100 99
tinit

Claims (19)

1. A composition which is storage stable at 20° C. comprising:
i) a carrier substance which is water-soluble or water-swellable and is in a glassy amorpous state;
ii) at least one material to be stored, which is unstable in aqueous solution at room temperature of 20° C. dissolved in said amorphous carrier substance, said composition existing in a glassy state at 20° C.
2. A composition according to claim 1 wherein the material to be stored is selected from proteins, peptides, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzyme cofactors, and derivatives of any of the foregoing having one or more additional moieties bound thereto.
3. A composition according to claim 1 having a water content not exceeding 4% by weight.
4. A composition according to claim 1 wherein the composition displays a glass transition temperature of at least 30° C.
5. A composition according to claim 1 wherein carrier substance is selected from carbohydrates and derivatives thereof which are polyhydroxy compounds.
6. A composition according to claim 5 wherein the carrier substance is a sugar polymer containing sugar residues linked through ether bridges to bifunctional groups other than carbohydrate.
7. A composition according to claim 1 wherein the carrier substance is a synthetic polymer.
8. A composition according to claim 1 wherein said material to be stored comprises a material which is unstable when alone in aqueous solution at room temperature.
9. A composition according to claim 1 wherein said material to be stored comprises a plurality of materials.
10. A composition according to claim 9 wherein said material to be stored comprises a plurality of materials which react together in aqueous solution.
11. A composition according to claim 1 which can be stored without refrigeration for at least 1 week.
12. A method of rendering a material storage stable a 20° C., which material is unstable in aqueous solution at room temperature of 20° C., comprising dissolving the material in a carrier substance which is water-soluble or water-swellable, or to a solution thereof, so that the material is dissolved in said carrier substance, and forming the resulting mixture into a glassy amorphous state, said mixture existing in said glassy state at 20° C.
13. A method according to claim 12 wherein forming the said mixture into an amorphous state is effected by evaporation under subatmospheric pressure.
14. A method according to claim 13 wherein evaporation is commenced at a temperature of 20 to 40° C. and subsequently continued at a temperature of 40 to 70° C.
15. A method according to claim 13 wherein the subatmospheric pressure is not greater than 90% of atmospheric.
16. In a method of storing a material, which material is unstable in aqueous solution at 20° C., the improvement comprising dissolving the material in a carrier substance which is water-soluble or water-swellable, or in a solution thereof, so that the material is dissolved in said carrier substance, forming the resulting mixture into a glassy amorphous state and storing the mixture in said glassy amorphous state without refrigeration for at least one week.
17. A composition which is storage-stable at 20° C., comprising:
( 1 ) a carrier substance which is water-soluble or water-swellable and is in a glassy state;
( 2 ) at least one material to be stored which is dissolved in said carrier substance;
wherein said composition exists in a glassy state at 20° C.;
wherein said at least one material comprises a purified biologically active material that is unstable in aqueous solution at 20° C.;
wherein said purified biologically active material is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzymes, enzyme cofactors and derivatives of any of the foregoing, said derivatives having one or more additional moieties bound thereto;
wherein said composition contains no more than 4 percent by weight of water; and
wherein said biological active material is not rennin.
18. A composition which is storage-stable at 20° C., comprising:
( 1 ) a carrier substance which is water-soluble or water-swellable and
( 2 ) at least one material to be stored which is dissolved in said carrier substance;
wherein said composition has the property that it exists in a glassy state when at 20° C.;
wherein said at least one material comprises a purified biologically active material that is unstable in aqueous solution at 20° C.;
wherein said biologically active material is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzymes, enzyme cofactors and derivatives of any of the foregoing, said
with proviso that when said at least one material comprises an enzyme, said enzyme comprises an enzyme selected from restriction enzymes, dehydrogenase enzymes, oxidase enzymes, and reductase enzymes.
19. A composition which is storage-stable at 20° C., comprising:
( 1 ) a carrier substance which is water-soluble or water-swellable and
( 2 ) at least one material to be stored which is dissolved in said carrier substance;
wherein said composition has the property that it exists in a glassy state when at 20° C;
wherein said at least one material comprises a purified biologically active material that is unstable in aqueous solution at 20° C;
wherein said biologically active material is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzymes, enzyme cofactors and derivatives of any of the foregoing, said derivatives having one or more additional moieties bound thereto; and
wherein said biologically active material is not freeze stable; and
with proviso that when said at least one material comprises an enzyme, said enzyme comprises an enzyme selected from dehydrogenase enzymes, restriction enzymes, oxidase enzymes, and reductase enzymes.
US09/939,689 1989-02-16 2001-08-28 Storage of materials Expired - Lifetime USRE39497E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/939,689 USRE39497E1 (en) 1989-02-16 2001-08-28 Storage of materials

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB898903593A GB8903593D0 (en) 1989-02-16 1989-02-16 Storage of materials
US07/479,939 US5098893A (en) 1989-02-16 1990-02-12 Storage of materials
US09/270,791 USRE37872E1 (en) 1989-02-16 1999-03-17 Storage of materials
US09/939,689 USRE39497E1 (en) 1989-02-16 2001-08-28 Storage of materials

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US07/479,939 Reissue US5098893A (en) 1989-02-16 1990-02-12 Storage of materials

Publications (1)

Publication Number Publication Date
USRE39497E1 true USRE39497E1 (en) 2007-02-27

Family

ID=27264327

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/939,688 Expired - Lifetime USRE38385E1 (en) 1989-02-16 2001-08-28 Storage of materials
US09/939,689 Expired - Lifetime USRE39497E1 (en) 1989-02-16 2001-08-28 Storage of materials

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/939,688 Expired - Lifetime USRE38385E1 (en) 1989-02-16 2001-08-28 Storage of materials

Country Status (1)

Country Link
US (2) USRE38385E1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060039985A1 (en) * 2004-04-27 2006-02-23 Bennett David B Methotrexate compositions
US20080147077A1 (en) * 2006-12-14 2008-06-19 Garigapati Venkata R Protein stabilization formulations
US20090259023A1 (en) * 2008-04-14 2009-10-15 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered gdf-5 formulations
US7964561B2 (en) 2007-06-29 2011-06-21 Advanced Technologies And Regenerative Medicine, Llc Protein formulations for use at elevated temperatures
US8058237B2 (en) 2007-08-07 2011-11-15 Advanced Technologies & Regenerative Medicine, LLC Stable composition of GDF-5 and method of storage
US8900856B2 (en) 2004-04-08 2014-12-02 Biomatrica, Inc. Integration of sample storage and sample management for life science
US9376709B2 (en) 2010-07-26 2016-06-28 Biomatrica, Inc. Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
US9845489B2 (en) 2010-07-26 2017-12-19 Biomatrica, Inc. Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
US10064404B2 (en) 2014-06-10 2018-09-04 Biomatrica, Inc. Stabilization of thrombocytes at ambient temperatures
US10568317B2 (en) 2015-12-08 2020-02-25 Biomatrica, Inc. Reduction of erythrocyte sedimentation rate

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
US20050147687A1 (en) * 2003-07-18 2005-07-07 Julia Rashba-Step Methods for fabrication, uses and compositions of small spherical particles of AAT prepared by controlled phase separation
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
US20050048127A1 (en) * 2003-07-22 2005-03-03 Larry Brown Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
CA2566075A1 (en) * 2004-05-12 2005-12-01 Baxter Healthcare S.A. Microspheres comprising protein and showing injectability at high concentrations of said agent
MXPA06012989A (en) * 2004-05-12 2007-06-12 Baxter Int Delivery of as-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes.
AU2005244842B2 (en) * 2004-05-12 2010-09-23 Baxter Healthcare S.A. Nucleic acid microspheres, production and delivery thereof
US20060260777A1 (en) * 2005-04-27 2006-11-23 Julia Rashba-Step Surface-modified microparticles and methods of forming and using the same
US20070281031A1 (en) * 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
JP5118139B2 (en) * 2006-08-04 2013-01-16 バクスター・インターナショナル・インコーポレイテッド Microsphere-based composition for preventing and / or reversing newly-onset autoimmune diabetes
AU2007319577A1 (en) * 2006-10-06 2008-05-22 Baxter Healthcare S.A. Microencapsules containing surface-modified microparticles and methods of forming and using the same
US20100047292A1 (en) * 2008-08-20 2010-02-25 Baxter International Inc. Methods of processing microparticles and compositions produced thereby
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8367427B2 (en) * 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles

Citations (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159826C (en) *
US125714A (en) * 1872-04-16 Improvement in medical compounds or phosphated candies
US586504A (en) * 1897-07-13 Otto marcsch
US1855591A (en) 1926-02-03 1932-04-26 Wallerstein Co Inc Invertase preparation and method of making the same
US2457036A (en) 1946-04-10 1948-12-21 Albert A Epstein Coffee concentrate and the process of producing it
US2648609A (en) * 1949-01-21 1953-08-11 Wisconsin Alumni Res Found Method of applying coatings to edible tablets or the like
US3300474A (en) * 1964-02-12 1967-01-24 Pharmacia Ab Sucrose ether copolymerizates
US3413198A (en) * 1966-06-30 1968-11-26 Calbiochem Reagents and method for assaying biological samples
US3456050A (en) * 1965-01-13 1969-07-15 Boehringer & Soehne Gmbh Dragee preparation
US3480468A (en) * 1965-02-12 1969-11-25 Farmaceutici Italia Process of preparing pharmaceutical tablet with orange-peel-like protective sugar coating
US3554767A (en) * 1964-04-23 1971-01-12 Merck Ag E Coated confectionery
US3694547A (en) * 1970-11-10 1972-09-26 Lever Brothers Ltd Anti-dandruff hair preparation
US4157386A (en) * 1978-05-18 1979-06-05 Rochelle Paul J Soft, chewable lozenge forming a sticky coating on teeth when combined with saliva in the mouth which is removable only by brushing
JPS5597096A (en) 1979-01-12 1980-07-23 Nec Corp High-speed mos driving circuit
US4372942A (en) * 1981-08-13 1983-02-08 Beecham Inc. Candy base and liquid center hard candy made therefrom
US4423086A (en) * 1979-10-17 1983-12-27 Roquette Freres Process for hard coating with sorbitol and products obtained thereby
GB2126588A (en) 1982-08-31 1984-03-28 Asahi Chemical Ind A method for stabilizing tumor necrosis factor and a stable aqueous solution or powder containing the same
EP0111216A2 (en) 1980-03-31 1984-06-20 Takeda Chemical Industries, Ltd. Method for enzyme immunoassay and peptide-enzyme conjugate, its lyophilizate, antibody and kit therefor
EP0140489A1 (en) 1983-08-05 1985-05-08 Wako Pure Chemical Industries, Ltd. Method for stabilizing immunologically active substances immobilized on an insoluble carrier and their use in the preparation of reagents for measuring physiologically active substances
US4551329A (en) * 1984-01-20 1985-11-05 Joan Harris Oral medicament lollipop
WO1986000336A1 (en) * 1984-06-25 1986-01-16 Suomen Sokeri Oy A stable glucose isomerase concentrate and a process for the preparation thereof
US4587267A (en) * 1983-09-15 1986-05-06 Standard Telephones And Cables, Plc Controlled release system
WO1986004095A1 (en) 1985-01-11 1986-07-17 Unilever Nv Preparation of reagents
WO1987000196A1 (en) * 1985-07-09 1987-01-15 Quadrant Bioresources Limited Protection of proteins and the like
EP0223221A2 (en) * 1985-11-21 1987-05-27 Roche Diagnostics GmbH Water soluble, stabilized peroxidase derivatives, process for their preparation and use in the determination of hydrogen peroxide
WO1987005300A2 (en) 1986-02-28 1987-09-11 Biocompatibles Limited Protein preservation
EP0244771A2 (en) * 1986-05-02 1987-11-11 Roche Diagnostics GmbH Stabilized soluble-dependent nitrate reductase, method for its production and its use
EP0252750A1 (en) * 1986-07-10 1988-01-13 EASTMAN KODAK COMPANY (a New Jersey corporation) Composition and analytical element having stabilized peroxidase
US4741872A (en) * 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules
US4749575A (en) * 1983-10-03 1988-06-07 Bio-Dar Ltd. Microencapsulated medicament in sweet matrix
US4753790A (en) * 1986-12-16 1988-06-28 Warner-Lambert Company Sorbitol coated comestible and method of preparation
US4762719A (en) * 1986-08-07 1988-08-09 Mark Forester Powder filled cough product
EP0297887A1 (en) 1987-06-29 1989-01-04 Quadrant Bioresources Limited Food process
US4824938A (en) * 1984-06-06 1989-04-25 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Water-soluble dry solid containing proteinaceous bioactive substance
US4847090A (en) * 1986-11-07 1989-07-11 Warner-Lambert Company Confection product and method for making same
US4849225A (en) * 1986-07-10 1989-07-18 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Process to prepare solid products containing oil-soluble substance
WO1989006542A1 (en) 1988-01-21 1989-07-27 Quadrant Bioresources Limited Preservation of viruses
US4863865A (en) * 1983-08-26 1989-09-05 Felix Franks Preservation by cold storage
US4873085A (en) * 1987-04-20 1989-10-10 Fuisz Pharmaceutical Ltd. Spun fibrous cosmetic and method of use
US4898781A (en) * 1986-11-07 1990-02-06 Showa Denko K.K. Water-soluble microcapsules
WO1990005182A1 (en) 1988-11-11 1990-05-17 Cranfield Biotechnology Ltd. Enzyme stabilisation
US4963359A (en) * 1989-01-30 1990-10-16 Plough, Inc. Non-cariogenic confections
US4985252A (en) * 1987-04-07 1991-01-15 R. I. Ph. Recherche Informatique Et Pharmacie (S.A.R.L.) Medication, dietetic product and hygienic product in the form of a powered composition obtained by adsorption of active ingredients on a rapidly dissolving sugar and process for obtaining said composition
US4997654A (en) * 1989-08-14 1991-03-05 Warner-Lambert Company Method for increasing salivation for xerostomia patients
EP0520748A1 (en) 1991-06-26 1992-12-30 Pafra Limited Storage of materials
USRE37872E1 (en) * 1989-02-16 2002-10-08 Inhale Therapeutics Systems, Inc. Storage of materials

Patent Citations (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US125714A (en) * 1872-04-16 Improvement in medical compounds or phosphated candies
US586504A (en) * 1897-07-13 Otto marcsch
DE159826C (en) *
US1855591A (en) 1926-02-03 1932-04-26 Wallerstein Co Inc Invertase preparation and method of making the same
US2457036A (en) 1946-04-10 1948-12-21 Albert A Epstein Coffee concentrate and the process of producing it
US2648609A (en) * 1949-01-21 1953-08-11 Wisconsin Alumni Res Found Method of applying coatings to edible tablets or the like
US3300474A (en) * 1964-02-12 1967-01-24 Pharmacia Ab Sucrose ether copolymerizates
US3554767A (en) * 1964-04-23 1971-01-12 Merck Ag E Coated confectionery
US3456050A (en) * 1965-01-13 1969-07-15 Boehringer & Soehne Gmbh Dragee preparation
US3480468A (en) * 1965-02-12 1969-11-25 Farmaceutici Italia Process of preparing pharmaceutical tablet with orange-peel-like protective sugar coating
US3413198A (en) * 1966-06-30 1968-11-26 Calbiochem Reagents and method for assaying biological samples
US3694547A (en) * 1970-11-10 1972-09-26 Lever Brothers Ltd Anti-dandruff hair preparation
US4157386A (en) * 1978-05-18 1979-06-05 Rochelle Paul J Soft, chewable lozenge forming a sticky coating on teeth when combined with saliva in the mouth which is removable only by brushing
JPS5597096A (en) 1979-01-12 1980-07-23 Nec Corp High-speed mos driving circuit
US4423086A (en) * 1979-10-17 1983-12-27 Roquette Freres Process for hard coating with sorbitol and products obtained thereby
EP0111216A2 (en) 1980-03-31 1984-06-20 Takeda Chemical Industries, Ltd. Method for enzyme immunoassay and peptide-enzyme conjugate, its lyophilizate, antibody and kit therefor
US4372942A (en) * 1981-08-13 1983-02-08 Beecham Inc. Candy base and liquid center hard candy made therefrom
GB2126588A (en) 1982-08-31 1984-03-28 Asahi Chemical Ind A method for stabilizing tumor necrosis factor and a stable aqueous solution or powder containing the same
EP0140489A1 (en) 1983-08-05 1985-05-08 Wako Pure Chemical Industries, Ltd. Method for stabilizing immunologically active substances immobilized on an insoluble carrier and their use in the preparation of reagents for measuring physiologically active substances
US4863865A (en) * 1983-08-26 1989-09-05 Felix Franks Preservation by cold storage
US4587267A (en) * 1983-09-15 1986-05-06 Standard Telephones And Cables, Plc Controlled release system
US4749575A (en) * 1983-10-03 1988-06-07 Bio-Dar Ltd. Microencapsulated medicament in sweet matrix
US4551329A (en) * 1984-01-20 1985-11-05 Joan Harris Oral medicament lollipop
US4824938A (en) * 1984-06-06 1989-04-25 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Water-soluble dry solid containing proteinaceous bioactive substance
WO1986000336A1 (en) * 1984-06-25 1986-01-16 Suomen Sokeri Oy A stable glucose isomerase concentrate and a process for the preparation thereof
WO1986004095A1 (en) 1985-01-11 1986-07-17 Unilever Nv Preparation of reagents
WO1987000196A1 (en) * 1985-07-09 1987-01-15 Quadrant Bioresources Limited Protection of proteins and the like
EP0229810B1 (en) 1985-07-09 1991-10-16 Quadrant Bioresources Limited Protection of proteins and the like
US4891319A (en) * 1985-07-09 1990-01-02 Quadrant Bioresources Limited Protection of proteins and the like
EP0223221A2 (en) * 1985-11-21 1987-05-27 Roche Diagnostics GmbH Water soluble, stabilized peroxidase derivatives, process for their preparation and use in the determination of hydrogen peroxide
US4910135A (en) * 1985-11-21 1990-03-20 Boehringer Mannheim Gmbh Water-soluble peroxidase derivatives
WO1987005300A2 (en) 1986-02-28 1987-09-11 Biocompatibles Limited Protein preservation
EP0244771A2 (en) * 1986-05-02 1987-11-11 Roche Diagnostics GmbH Stabilized soluble-dependent nitrate reductase, method for its production and its use
US4741872A (en) * 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules
US4849225A (en) * 1986-07-10 1989-07-18 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Process to prepare solid products containing oil-soluble substance
EP0252750A1 (en) * 1986-07-10 1988-01-13 EASTMAN KODAK COMPANY (a New Jersey corporation) Composition and analytical element having stabilized peroxidase
US4762719A (en) * 1986-08-07 1988-08-09 Mark Forester Powder filled cough product
US4847090A (en) * 1986-11-07 1989-07-11 Warner-Lambert Company Confection product and method for making same
US4898781A (en) * 1986-11-07 1990-02-06 Showa Denko K.K. Water-soluble microcapsules
US4753790A (en) * 1986-12-16 1988-06-28 Warner-Lambert Company Sorbitol coated comestible and method of preparation
US4985252A (en) * 1987-04-07 1991-01-15 R. I. Ph. Recherche Informatique Et Pharmacie (S.A.R.L.) Medication, dietetic product and hygienic product in the form of a powered composition obtained by adsorption of active ingredients on a rapidly dissolving sugar and process for obtaining said composition
US4873085A (en) * 1987-04-20 1989-10-10 Fuisz Pharmaceutical Ltd. Spun fibrous cosmetic and method of use
EP0297887A1 (en) 1987-06-29 1989-01-04 Quadrant Bioresources Limited Food process
WO1989006542A1 (en) 1988-01-21 1989-07-27 Quadrant Bioresources Limited Preservation of viruses
WO1990005182A1 (en) 1988-11-11 1990-05-17 Cranfield Biotechnology Ltd. Enzyme stabilisation
US4963359A (en) * 1989-01-30 1990-10-16 Plough, Inc. Non-cariogenic confections
USRE37872E1 (en) * 1989-02-16 2002-10-08 Inhale Therapeutics Systems, Inc. Storage of materials
US4997654A (en) * 1989-08-14 1991-03-05 Warner-Lambert Company Method for increasing salivation for xerostomia patients
EP0520748A1 (en) 1991-06-26 1992-12-30 Pafra Limited Storage of materials

Non-Patent Citations (64)

* Cited by examiner, † Cited by third party
Title
"The Journal of Physical Chemistry," vol. 78, No. 28, 1974; Dependence of the Glass Transition Temperature on Heating and Cooling Rate, pp. 2673-2677.
"The Spray Drying of Enzyme Rennin", Vipin Dhirajlal Shah, University Microfilms, Inc., Ann Arbor Michigan, (1963).
A Polymer Physico-Chemical Approach to the Study of Commercial Starch Hydrolysis Products (SHPs), Harry Levine and Louise Slade, Carbohydrate Polymers, 6 pp. 213-244 (1986).
Analects(R), Promotional Lecture, (not dated-1992 or later).
Another View of Trehalose for Drying and Stabilizing Biological Materials, Levine and Slade, BioPharm, 1992.
BioPharm, Roser, Biopharm, pp. 49-53, Sep. 1991.
Clas et al., Differential Scanning Calorimentry: Applications in Drug Development,; Research Focus/Reviews vol. 2, No. 8 Aug. 1999, pp. 311-320.
Dec. 3, 1999 letter from Eric Potter Clarkson to EPO re: Opposition to European patent Application No. 90301561.8 (0383569).
Declaration under 37 CFR 1.132 re: Franks et al. U.S. Appl. No. 08/241,457, filed May 11, 1994; for storage of materials dated Feb. 23, 1996.
Developments in Biological Standardization, Pikal and Sah International Symposium on Biological Product Freeze-Drying and Formulation Bethesda, USA, 74 pp. 165-170 (1991).
Dielectric Studies of Protein Hydration and Hydration-induced Flexibility, Bone and Pethig, J. Mol. Biol., 181 pp. 323-326, (1985).
Document in No. 92 305 769.9-Communication/Minutes (Annex) dated Jul. 17, 1998.
Fax from Eric Potter Clarkson to EPO dated Oct. 15, 1999 re: Further Submissions of Novo Nordisk (Opponent 2).
Green and Angell, J. Phys. Chem, 89, 2880 (1989).
Green et al., "The Journal of Physical Chemistry," Phase Relations and Vitrification in Saccharide-Water Solutions and the Trehalose Anomaly vol. 93, No. 8, 1989, pp. 2880-2882.
Hatley et al. Biotechnology & Applied Biochemistry, vol. 11, pp. 367-370 (1989). *
Hatley et al. Process Biochemistry, pp. 169-172 (Dec. 1987). *
Hydration-induced Conformational and Flexibility Changes of Lysozyme at Low Water Content, P.L. Poole and J.L. Finney, Int J. Biol. Macromol., 5 pp. 308-310 (1983).
Japanese patent publication Sho 60-244288 (1985-244288) 1985, (translation).
Labrude et al., "Journal of Pharmaceutical Sciences; vol. 78, No. 3, Mar. 1989"; pp. 223-229.
Labrude et al., s.t.p. pharma, Jun. 1988 No. 6; pp. 472-480.
Loss of Structure in Freeze-dried Carbohydrates Solutions: Effect of Temperature, Moisture Content and Composition, Spyros Tsourouflis, James M. Flink, and Marcus Karel, J Sci Fd-Agric 27, pp. 509-519 (1976).
Lyophilization of Biotechnology Products, Arno T. P. Skrabanaja, Andre L. J. De Meere, Rein A. De Ruiter, and Piet J.M. Van Den Detelaar, PDA Journal, 48-6 pp. 311-317 (1994).
Mar. 6, 2000 letter/fax from Mewburn Ellis to EPO.
Modes of Stabilization of a Protein by Organic Solutes during Desiccation; John F. Carpenter and John H. Crowe, Department of Zoology, University of California, Davis, California Cryobiology 25 pp. 459-470 (1988).
Nov. 1, 1999 fax from Simmons & Simmons, containing claim form and draft amended pleadings.
Nov. 29, 1999 letter from Mewburn Ellis to EPO.
Oct. 14, 1999 letter from Mewburn Ellis to EPO.
Oct. 26, 1999 letter/fax from Mewburn Ellis to EPO containing: letter dated Oct. 15, 1999 to EPO from Akzo Nobel.
Opinion in Inhale v. Quadrant, Case No. HC1999 No. 04555, (Jun. 20, 2001).
Opposition by Quardant to Inhale EP 0,383,569; Declaration by Nicholas David Osborne, (unsigned; Sep. 1999).
Opposition by Quardant to Inhale EP 0,383,569; Declaration by Trevor George Gard, (unsigned; Sep. 1999).
Permazyme Tehcnology, Permazyme leaflet, (not dated).
Physical Characterization of Spray Dried Sugars Suitable A Carriers in Inhalation Systems, Venkatesh Naini, Peter R. Byron and Elaine M. Phillips, Aerosol Research Group, Poster at Tenth annual AAPS, Miami, FL-PT6180, (not dated).
Polinsky et al. Proc. Natl. Acad. Sci. USA, vol. 72, No. 9, pp. 3310-3314 (1975). *
Preservation of the Enzymatic Activity of Rennin during Spray Drying and During Storage, and the Effect of Sugars and Certain Other Additives, M. J. van de Beek and S. y. Gerisma, Neth Mild Dairy J. 23 pp. 46-5 (1969).
Principles of "Cryostabilization" Technology from Structure/Property Relationships of Carbohydrate/Water systems-A Review, Harry Levine and Louise Slade, Nabisco Brands, inc., Corporate Technology Group, Cryoletters 9 pp. 21-63 (1988).
Production of Trehalose Dried Eggs, Quandrant Experimental Data, (not dated).
Protein Hydration and Enzyme Activity: The Role of Hydration-induced Conformation and Dynamic changes in the Activity of Lysozyme, J.L. Finney and P.L. Poole, Comments Mol Cell Biophys, 2 pp. 129-151 (1984).
Psychrometric Chart, (not dated).
Pure and Applied Chemistry, vol. 60, 1841-1864, Slade and Levine, "Non-Equilibrium Behavior of Small Carbohydrate Water System". *
Ready-To-To(TM) DNA Labeling Kit, Promotional Lecture, (not dated).
Ready-To-To(TM) Kits for a broad range of Techniques in Molecular Biology, Designed for results-mot surprises, Promotional Lecture, (not dated).
ROOS-Carbohydrate Research, 238, 39-48 (1993).
Sep. 13, 1999 letter from Gill Jennings & Every to EPO.
Sep. 20, 1999 Letter from Gill Jennings & Every to EPO.
Sequential Hydration of a Dry Globular Protein, P.L. Poole and J.L. Finney, Biopolymers, 22 pp. 255-260 (1983).
Slade et al, Non-Equilibrium Behaviour of Small Carbohydrate Water Systems. Pure and Applied Chemistry. vol. 60, No. 12, pp. 1841-1864 (1988). *
Some Physico-Chemical Properties of Lactose, B. L. Herrington. J Dairy Science, 17, pp. 501-519, (1934).
Stabilization of Phosphofructokinase during Air-Drying with Sugars and Sugar/Transition Metal Mixtures, John f. Carpenter, Beth Martin, Lois M. Crowe, and John H. Crowe, Cryobiology, 24 pp. 455-464 (1987).
Structural Stability of Intermediate Moisture Foods-A New Understanding, Louise Slade and H. Levine, Food Structure, its Creation and Evaluation, Blanshard and Mitchell, pp. 115-180 (1988).
Structure and Structure Transitions in Dried Carbohydrate Materials, James M. Flink, Physical Properties of Foods, pp. 473-521 (1983).
Supplemental Amendment re: Franks et al. U.S. Appl. No. 08/241,457, filed May 11, 1994; for storage of materials dated Apr. 22, 1996.
The Condensed Chemical Dictionary, Seventh Edition, Arthur and Elizabeth Rose, Reinhold Publishing Corporation, p. 448 (1961).
The Crystalisation of Hydrates From Amorphous Carbohydrates, Barry J. Aldous, Anthony D. Auffret, and Felix Franks, Cryo-Letters, 16 pp. 181-186 (1995).
The Effect of Sugars on the Thermal Denatation of Lysozyme H7H Uedaira Bull chem Soc 53 2451 (1980).
The Glassy State and Survival of Anhydrous Biological Systems, Michael J. Burke, pp. 358-363, (1986) in Membranes, Metabolism, and Dry Organisms. A.C. Leopold, ed.
The Glassy State in Certain Sugar-Containing Food Products, G.W. White and S. H. Cakebread, J Food Technol. 1, pp. 73-82 (1966).
The Nature of the Glassy State and the Behavior of Liquids at Low Temperatures, Kauzmann Chem Rev 43, pp. 219-227 (1948).
The New Encyclopedia Britannica, vol. 16, Encyclopedia Britannica, Inc., p. 476-479 (1985).
Thermostability of Enzyme in the Three-dimensional Network of Polysaccharide Chains, Z. Schneider, A. Stroinski and J. Pawelkiewiz, Bulletin de L'Acad. Polonnaise des Sciences XV1,4, pp. 203 and 204 (1968).
Use of Lyoprotectants in the Freeze-Drying of a Model Protein, Ribonuclease, Michael W. Townsend and Patrick P. DeLuca, Journal of Parenteral Science & Technology, 42 pp. 190-199 (1988).
Vo. 41. No. 9, 1968; "Glass Transition in Dehydrated Amorphous Solid", Bull. Chem. Soc. Japan, p. 2322.
Walter Relations of Foods, R.B. Duckworth, Editor, Academic Press, p. 648 (1975).

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9078426B2 (en) 2004-04-08 2015-07-14 Biomatrica, Inc. Integration of sample storage and sample management for life science
US8900856B2 (en) 2004-04-08 2014-12-02 Biomatrica, Inc. Integration of sample storage and sample management for life science
US20060039985A1 (en) * 2004-04-27 2006-02-23 Bennett David B Methotrexate compositions
US8435943B2 (en) 2006-12-14 2013-05-07 Advanced Technogies And Regenerative Medicine, Llc Protein stabilization formulations
US20080147077A1 (en) * 2006-12-14 2008-06-19 Garigapati Venkata R Protein stabilization formulations
US7956028B2 (en) 2006-12-14 2011-06-07 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US20110237506A1 (en) * 2006-12-14 2011-09-29 Advanced Technologies And Regenerative Medicine, Llc Protein stabilization formulations
US8895506B2 (en) 2006-12-14 2014-11-25 DePuy Synthes Products, LLC Protein stabilization formulations
US7964561B2 (en) 2007-06-29 2011-06-21 Advanced Technologies And Regenerative Medicine, Llc Protein formulations for use at elevated temperatures
US8058237B2 (en) 2007-08-07 2011-11-15 Advanced Technologies & Regenerative Medicine, LLC Stable composition of GDF-5 and method of storage
US7947649B2 (en) 2008-04-14 2011-05-24 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered GDF-5 formulations
US20090259023A1 (en) * 2008-04-14 2009-10-15 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered gdf-5 formulations
US9376709B2 (en) 2010-07-26 2016-06-28 Biomatrica, Inc. Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures
US9845489B2 (en) 2010-07-26 2017-12-19 Biomatrica, Inc. Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
US9999217B2 (en) 2010-07-26 2018-06-19 Biomatrica, Inc. Compositions for stabilizing DNA, RNA, and proteins in blood and other biological samples during shipping and storage at ambient temperatures
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
US10064404B2 (en) 2014-06-10 2018-09-04 Biomatrica, Inc. Stabilization of thrombocytes at ambient temperatures
US10772319B2 (en) 2014-06-10 2020-09-15 Biomatrica, Inc. Stabilization of thrombocytes at ambient temperatures
US11672247B2 (en) 2014-06-10 2023-06-13 Biomatrica, Inc. Stabilization of thrombocytes at ambient temperatures
US10568317B2 (en) 2015-12-08 2020-02-25 Biomatrica, Inc. Reduction of erythrocyte sedimentation rate
US11116205B2 (en) 2015-12-08 2021-09-14 Biomatrica, Inc. Reduction of erythrocyte sedimentation rate

Also Published As

Publication number Publication date
USRE38385E1 (en) 2004-01-13

Similar Documents

Publication Publication Date Title
USRE37872E1 (en) Storage of materials
USRE39497E1 (en) Storage of materials
EP0376361B2 (en) Enzyme Stabilisation
US5928469A (en) Process for storage of materials
US6294365B1 (en) Method and formulation for stabilization of enzymes
EP1303184B1 (en) Preservation and storage medium for biological materials
US4189401A (en) Method of storing a biological reference control standard and biological reference control standard obtained thereby
US3860484A (en) Enzyme stabilization
CA2040815C (en) Enzyme stabilisation
EP0726310A1 (en) Stabilized enzyme compositons for nucleic acid amplification
US4931392A (en) Process for stabilizing kinase
US4188465A (en) Stabilized urease composition
EP1418229B1 (en) Method of stabilizing alkaline phosphatase
US20030091971A1 (en) Composition for stabilizing biological materials
US4219645A (en) Stabilized nicotinamide-adenine dinucleotides and process for their preparation
CN1286725A (en) Preservation of sensitive biological samples by vitrification
WO1995022602A1 (en) Isoenzyme calibrator/control products
JPH08228774A (en) Stabilization of peroxidase or peroxidase-labeled antibody
Kaul et al. Storage stability of enzymes in dry apolar solvent
JPH0411887A (en) Method for stabilizing enzyme

Legal Events

Date Code Title Description
AS Assignment

Owner name: NEKTAR THERAPEUTICS, CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:INHALE THERAPEUTIC SYSTEMS, INC.;REEL/FRAME:013525/0753

Effective date: 20030113

AS Assignment

Owner name: NOVARTIS PHARMA AG,SWITZERLAND

Free format text: ASSIGNMENT OF PATENT RIGHTS;ASSIGNOR:NEKTAR THERAPEUTICS;REEL/FRAME:022071/0001

Effective date: 20081231

Owner name: NOVARTIS PHARMA AG, SWITZERLAND

Free format text: ASSIGNMENT OF PATENT RIGHTS;ASSIGNOR:NEKTAR THERAPEUTICS;REEL/FRAME:022071/0001

Effective date: 20081231